EMA Application withdrawn: Tuzodi (Midazolam Hydrochloride) — Regulatory Pharma Net S.r.l.

View source ↗

Summary

The EMA has withdrawn the application for Tuzodi (Midazolam Hydrochloride) by Regulatory Pharma Net S.r.l., for seizures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Tuzodi (Midazolam Hydrochloride)

Snippet

Status: Application withdrawn. Therapeutic area: Seizures. MAH: Regulatory Pharma Net S.r.l.